(SLNO) Soleno Therapeutics - Overview
Stock: Diazoxide, Prader-Willi, Rare Diseases, Clinical Trials
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 76.8% |
| Relative Tail Risk | -18.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.02 |
| Alpha | -30.78 |
| Character TTM | |
|---|---|
| Beta | 0.699 |
| Beta Downside | 0.817 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.42% |
| CAGR/Max DD | 3.03 |
Description: SLNO Soleno Therapeutics January 08, 2026
Soleno Therapeutics Inc. (NASDAQ:SLNO) is a clinical-stage biopharma focused on rare-disease therapeutics. Founded in 1999 and rebranded from Capnia in 2017, the company is headquartered in Redwood City, California, and trades as a common stock within the U.S. biotechnology sub-industry.
Its lead asset is Diazoxide Choline Extended-Release (DCE-R), a once-daily oral tablet currently in a pivotal Phase III trial for Prader-Willi Syndrome (PWS), a genetic disorder affecting ~1 in 15,000 births. Successful Phase III data could position DCE-R as the first FDA-approved therapy for PWS, a market estimated at >$200 million annual sales potential given the unmet need and high willingness-to-pay in rare-disease pricing.
As of the latest 10-Q (Q3 2024), Soleno reported a cash balance of roughly $68 million, providing runway into late 2025 assuming no major capital raises; its burn rate has trended down ~15% YoY due to trial-cost efficiencies. The broader biotech sector is benefiting from a 7% CAGR in rare-disease R&D spend, driven by favorable regulatory incentives (e.g., Orphan Drug Designation) and expanding payer coverage for high-impact therapies. For investors seeking deeper quantitative analysis, a quick look at ValueRay’s detailed financial model can help surface the key upside and downside scenarios.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -78.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA 13.11 > 1.0 |
| NWC/Revenue: 508.3% < 20% (prev 7059 %; Δ -6550 % < -1%) |
| CFO/TA -0.04 > 3% & CFO -25.7m > Net Income -78.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 16.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (54.9m) vs 12m ago 31.14% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 22.01% > 50% (prev 1.16%; Δ 20.85% > 0%) |
| Interest Coverage Ratio: -15.68 > 6 (EBITDA TTM -66.3m / Interest Expense TTM 4.36m) |
Altman Z'' -2.86
| A: 0.84 (Total Current Assets 534.9m - Total Current Liabilities 33.3m) / Total Assets 599.9m |
| B: -0.79 (Retained Earnings -474.7m / Total Assets 599.9m) |
| C: -0.15 (EBIT TTM -68.3m / Avg Total Assets 448.3m) |
| D: -4.51 (Book Value of Equity -474.3m / Total Liabilities 105.1m) |
| Altman-Z'' Score: -2.86 = D |
What is the price of SLNO shares?
Over the past week, the price has changed by +7.70%, over one month by -9.99%, over three months by -4.62% and over the past year by -18.54%.
Is SLNO a buy, sell or hold?
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SLNO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 111.9 | 169.5% |
| Analysts Target Price | 111.9 | 169.5% |
| ValueRay Target Price | 50.7 | 22.1% |
SLNO Fundamental Data Overview February 03, 2026
P/S = 20.9887
P/B = 4.1878
Revenue TTM = 98.7m USD
EBIT TTM = -68.3m USD
EBITDA TTM = -66.3m USD
Long Term Debt = 49.9m USD (from longTermDebt, last quarter)
Short Term Debt = 697.0k USD (from shortTermDebt, last quarter)
Debt = 2.81m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -243.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.57b USD (2.07b + Debt 2.81m - CCE 498.9m)
Interest Coverage Ratio = -15.68 (Ebit TTM -68.3m / Interest Expense TTM 4.36m)
EV/FCF = -61.18x (Enterprise Value 1.57b / FCF TTM -25.7m)
FCF Yield = -1.63% (FCF TTM -25.7m / Enterprise Value 1.57b)
FCF Margin = -26.09% (FCF TTM -25.7m / Revenue TTM 98.7m)
Net Margin = -79.50% (Net Income TTM -78.5m / Revenue TTM 98.7m)
Gross Margin = unknown ((Revenue TTM 98.7m - Cost of Revenue TTM 1.84m) / Revenue TTM)
Tobins Q-Ratio = 2.63 (Enterprise Value 1.57b / Total Assets 599.9m)
Interest Expense / Debt = 49.48% (Interest Expense 1.39m / Debt 2.81m)
Taxrate = 21.0% (US default 21%)
NOPAT = -54.0m (EBIT -68.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.08 (Total Current Assets 534.9m / Total Current Liabilities 33.3m)
Debt / Equity = 0.01 (Debt 2.81m / totalStockholderEquity, last quarter 494.8m)
Debt / EBITDA = 3.68 (negative EBITDA) (Net Debt -243.9m / EBITDA -66.3m)
Debt / FCF = 9.47 (negative FCF - burning cash) (Net Debt -243.9m / FCF TTM -25.7m)
Total Stockholder Equity = 303.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.50% (Net Income -78.5m / Total Assets 599.9m)
RoE = -25.88% (Net Income TTM -78.5m / Total Stockholder Equity 303.1m)
RoCE = -19.36% (EBIT -68.3m / Capital Employed (Equity 303.1m + L.T.Debt 49.9m))
RoIC = -15.29% (negative operating profit) (NOPAT -54.0m / Invested Capital 352.9m)
WACC = 8.53% (E(2.07b)/V(2.07b) * Re(8.49%) + D(2.81m)/V(2.07b) * Rd(49.48%) * (1-Tc(0.21)))
Discount Rate = 8.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 44.37%
Fair Price DCF = unknown (Cash Flow -25.7m)
EPS Correlation: 47.69 | EPS CAGR: 24.92% | SUE: -0.41 | # QB: 0
Revenue Correlation: 57.33 | Revenue CAGR: 89.54% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.75 | Chg30d=+0.062 | Revisions Net=+5 | Analysts=12
EPS next Year (2026-12-31): EPS=4.21 | Chg30d=+0.097 | Revisions Net=-2 | Growth EPS=+1336.5% | Growth Revenue=+158.1%